What's Next For Bristol's Opdivo/Yervoy Combination
Updated data from CheckMate 012 of Yervoy/Opdivo in first-line lung cancer bode well for the Phase III CheckMate 227 study, plus other indications, Bristol says.
You may also be interested in...
Bristol-Myers Squibb's Opdivo plus Yervoy in first-line RCC did not achieve statistical significance in terms of progression-free survival versus Sutent, but overall survival data aren't available yet.
Bristol stresses comprehensive approach to lung cancer – its top priority – with trials from early to late stages, a thoughtful biomarker development program and a pipeline stocked with drugs that have a wide range of targets.
Merck’s Keytruda improved progression-free survival and overall survival in previously untreated non-small cell lung cancer patients in the highly-anticipated KEYNOTE-024 trial, all but guaranteeing a rapid FDA approval in the indication.